An exciting overview of progress made by the startup Tome Biosciences towards clinical application of the PASTE technology, a way of using CRISPR and integrases (or ligases) to programmably insert very long DNA sequences into the human genome.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tome Biosciences inserts large DNA sequences into precise genomic locations, overcoming limitations of base and prime editing.